News >

Novel Therapies Bring Hope in Biliary Tract Cancers

Danielle Bucco
Published: Wednesday, Mar 21, 2018

John Gordan, MD, PhD

John Gordan, MD, PhD
The only curative treatment for patients with biliary tract cancers is surgical resection; however, a majority of patients will have disease recurrence, explains John Gordan, MD, PhD, creating a population with a high unmet need that researchers attempting to address.

State of the Science Summit™ on Gastrointestinal Cancers, Gordan, an assistant professor, Division of Hematology/Oncology, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discussed the challenges of treating patients with biliary tract cancers and novel therapies in development.

OncLive: Please provide an overview of your presentation on novel therapies in biliary tract cancers.

Gordan: My presentation was focused on what lies ahead in the treatment of biliary tract cancers. Unlike other gastrointestinal malignancies, where we have established paradigms for second- and third-line therapy, biliary tract cancers are quite rare and genetically complex. As a result, their progress has been slower. Things have changed dramatically in the last 2 or 3 years with the broad adoption of molecular diagnostics. We are now defining therapeutically targetable subsets in this disease for which we have potent and active agents. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication